Last reviewed · How we verify
Ensifentrine Dose 1
Ensifentrine is a dual inhibitor of the cystic fibrosis transmembrane conductance regulator (CFTR) and the epithelial sodium channel (ENaC).
Ensifentrine is a dual inhibitor of the cystic fibrosis transmembrane conductance regulator (CFTR) and the epithelial sodium channel (ENaC). Used for Cystic fibrosis.
At a glance
| Generic name | Ensifentrine Dose 1 |
|---|---|
| Sponsor | Verona Pharma Inc |
| Drug class | CFTR and ENaC inhibitor |
| Target | CFTR and ENaC |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 2 |
Mechanism of action
By inhibiting CFTR and ENaC, ensifentrine increases the chloride ion conductance across epithelial membranes, leading to improved lung function in patients with cystic fibrosis. This dual inhibition also reduces sodium absorption, further contributing to the therapeutic effect.
Approved indications
- Cystic fibrosis
Common side effects
- Nausea
- Vomiting
- Headache
- Diarrhea
Key clinical trials
- A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD (PHASE2)
- A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease (PHASE2)
- A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD (PHASE3)
- A Phase 3 Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD (PHASE3)
- A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Nebulized Ensifentrine in Healthy Chinese Subjects (PHASE1)
- Study Evaluating 5 Doses of RPL554 and Placebo in COPD Patients Via a Dry Powder Inhaler (PHASE2)
- Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19 (PHASE2)
- A Study of RPL554 Drug Administered by Metered Dose Inhaler to Treat Chronic Obstructive Pulmonary Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ensifentrine Dose 1 CI brief — competitive landscape report
- Ensifentrine Dose 1 updates RSS · CI watch RSS
- Verona Pharma Inc portfolio CI